For patients with AF complicated by ACS treated by uncomplicated PCI, early discontinuance of aspirin (up to 1 week from the acute incident) and DAT (NOAC plus a P2Y12 inhibitor, preferably clopidogrel) should be considered as one default strategy for up to 1 year if stent thrombosis (ST) risk is low or if bleeding risks exceed the ST risk, irrespective of the type of stent used, and OAC monotherapy should proceed thereafter. The gene discussed is P2RY12; the disease is atrial fibrillation.